Literature DB >> 21252725

Complement and correction for meta-analysis of patients with extensive-stage small cell lung cancer managed with irinotecan/cisplatin versus etoposide/cisplatin as first-line chemotherapy.

Shanxian Guo, Yonggang Liang, Qinghua Zhou.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21252725     DOI： 10.1097/JTO.0b013e3182061d8c

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  3 in total

1.  Inhibitory effect of trans-ferulic acid on proliferation and migration of human lung cancer cells accompanied with increased endogenous reactive oxygen species and β-catenin instability.

Authors:  Yao Fong; Chia-Chun Tang; Huei-Ting Hu; Hsin-Yu Fang; Bing-Hung Chen; Chang-Yi Wu; Shyng-Shiou Yuan; Hui-Min David Wang; Yen-Chun Chen; Yen-Ni Teng; Chien-Chih Chiu
Journal:  Chin Med       Date:  2016-10-01       Impact factor: 5.455

2.  [First-line Chemotherapy for Extensive-disease Small Cell Lung Cancer: 
A Network Meta-analysis].

Authors:  Yujie Chen; Lingxiao Chen; Diansheng Zhong; Jing Wang; Lina Peng; Xin Feng
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2016-04-20

3.  A Phase III Randomized Study Comparing a Chemotherapy with Cisplatin and Etoposide to a Etoposide Regimen without Cisplatin for Patients with Extensive Small-Cell Lung Cancer.

Authors:  Thierry Berghmans; Arnaud Scherpereel; Anne-Pascale Meert; Vicente Giner; Jacques Lecomte; Jean-Jacques Lafitte; Nathalie Leclercq; Marianne Paesmans; Jean-Paul Sculier
Journal:  Front Oncol       Date:  2017-09-19       Impact factor: 6.244
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.